Vitamin E-based nanomedicines for anti-cancer drug delivery

J Control Release. 2014 May 28:182:33-44. doi: 10.1016/j.jconrel.2014.03.009. Epub 2014 Mar 12.

Abstract

This review aims to highlight the development of novel vitamin E conjugates for the vectorization of active pharmaceutical ingredients through nanotechnologies. The physico-chemical and biological properties of vitamin E derivatives offer multiple advantages in drug delivery like biocompatibility, improvement of drug solubility and anticancer activity. Nanomedicines have shown high potential in drug delivery since (i) they may offer better drug biopharmaceutical properties such as longer half-life or better bioavailability and (ii) they have shown benefits in cancer therapy by improving anticancer drug therapeutic index. Vitamin E-based nanomedicines were developed to combine the pharmaceutical properties of both vitamin E and nanomedicines for two purposes: (i) to improve water solubility of hydrophobic drugs and (ii) to enhance the therapeutic efficiency of anticancer agents. This review is divided into three parts: the first one describes the biology and the metabolic functions of vitamin E, the second one focuses on the anticancer activity of two vitamin E derivatives: vitamin E succinate (TOS) and vitamin E polyethylene glycol-succinate (TPGS). Finally, in the third part, we discuss vitamin E derivatives based-nanomedicines.

Keywords: Anticancer drug; Drug delivery; TOS; TPGS; Vitamin E.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Drug Delivery Systems*
  • Humans
  • Nanomedicine
  • Neoplasms / drug therapy
  • Vitamin E / administration & dosage*
  • Vitamin E / chemistry

Substances

  • Antineoplastic Agents
  • Vitamin E